163 related articles for article (PubMed ID: 25654738)
1. The genetic basis of new treatment modalities in melanoma.
Kunz M
Curr Drug Targets; 2015; 16(3):233-48. PubMed ID: 25654738
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes in melanoma: an update.
Kunz M
Eur J Cell Biol; 2014; 93(1-2):1-10. PubMed ID: 24468268
[TBL] [Abstract][Full Text] [Related]
3. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
Kunz M; Hölzel M
Cancer Metastasis Rev; 2017 Mar; 36(1):53-75. PubMed ID: 28210865
[TBL] [Abstract][Full Text] [Related]
4. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
5. Ras, Raf, and MAP kinase in melanoma.
Solus JF; Kraft S
Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
Griewank KG; Schilling B
Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
[TBL] [Abstract][Full Text] [Related]
10. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
11. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
12. New developments in dermatological oncogenetics.
Kunz M
J Dtsch Dermatol Ges; 2013 Sep; 11(9):831-6. PubMed ID: 23957481
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
14. Melanoma therapy: Check the checkpoints.
Furue M; Kadono T
J Dermatol; 2016 Feb; 43(2):121-4. PubMed ID: 26813076
[TBL] [Abstract][Full Text] [Related]
15. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
16. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.
Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D
Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541
[TBL] [Abstract][Full Text] [Related]
17. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
18. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in melanoma.
Moschos SJ; Pinnamaneni R
Surg Oncol Clin N Am; 2015 Apr; 24(2):347-58. PubMed ID: 25769717
[TBL] [Abstract][Full Text] [Related]
20. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]